Sarepta Therapeutics Inc. (SRPT) released some pretty compelling three-year data on Monday that shows its gene therapy Elevidys continues delivering meaningful benefits for patients with Duchenne muscular dystrophy. This isn't just a small effect that shows up in statistical models—patients are actually maintaining their ability to move around while untreated patients continue to decline.
The results come from Part 1 of the EMBARK Phase 3 study, which tracked 52 patients who received Elevidys and compared them to 73 untreated controls. Here's what makes this interesting: three years after a single treatment, the Elevidys patients still had motor function scores above where they started, while the control group continued showing the age-related decline you'd expect with this progressive muscle-wasting disease.
The numbers tell a clear story. On the North Star Ambulatory Assessment—a key measure of motor function in Duchenne—treated patients maintained scores above baseline while controls dropped below theirs. For Time to Rise tests (how long it takes to stand up from the floor), Elevidys slowed disease progression by 73%. For the 10-meter walk/run test, the slowing was 70%. Those are substantial differences that translate to real-world functional ability.
Perhaps equally important: no new safety signals showed up in the three-year data. For a gene therapy that's been administered to over 1,200 patients globally at this point, that's reassuring news for both doctors and families considering treatment.
The Roche Partnership and Expanding Access
Sarepta isn't going it alone here. Since 2019, they've partnered with Roche Holdings AG (RHHBY) to expand Elevidys globally. The division of labor is straightforward: Sarepta handles U.S. approval, manufacturing, and sales, while Roche manages international regulatory work and distribution (except Japan, where Chugai Pharmaceuticals leads commercialization).
The FDA has been supportive of expanding the program. Last November, regulators approved an updated label making Elevidys available to ambulatory patients aged four and above. Around the same time, the FDA greenlit dosing in Cohort 8 of the ENDEAVOR study, which is testing an enhanced immunosuppressive regimen for non-ambulant patients—those who've already lost the ability to walk. That's a meaningful expansion of the potential patient population.
The Financial Picture
Elevidys is turning into a significant commercial success for Sarepta. The company reported preliminary fourth-quarter product revenue of $369.6 million and full-year 2025 revenue of $1.86 billion across all products. Elevidys specifically brought in $110.4 million in the fourth quarter and $898.7 million for the full year—not quite hitting the billion-dollar mark, but getting close.
Investors seemed pleased with the three-year data. Sarepta shares jumped 5.06% to $22.20 in premarket trading Monday following the announcement.
The ongoing analysis includes data from crossover patients—those who initially didn't receive treatment but later got Elevidys—and their two-year results. That additional data should help fill out the picture of how the therapy performs across different treatment timelines and patient populations.
